Logo
x

Search

Subscribe Now

Eli lilly

Eli Lilly Reports the US FDA’s Approval of Zepbound (Tirzepatide) to Treat Moderate-to-Severe Obstructive Sleep Apnea in Obese Adults

Eli Lilly Reports the US FDA’s Approval of Zepbound (Tirzepatide) to Treat Moderate-to-Severe Obstructive Sleep Apnea in Obese Adu...

  • December 23, 2024
Eli Lilly Reports Kinsula (Donanemab-Azbt) Approval in China to Treat Early Symptomatic Alzheimer's Disease

Eli Lilly Reports Kinsula (Donanemab-Azbt) Approval in China to Treat Early Symptomatic Alzheimer's Disease

  • December 19, 2024
Eli Lilly Reports the CHMP’s Positive Opinion of Omvoh (Mirikizumab) to Treat Moderate to Severe Active Crohn's Disease

Eli Lilly Reports the CHMP’s Positive Opinion of Omvoh (Mirikizumab) to Treat Moderate to Severe Active Crohn's Disease

  • December 16, 2024
Eli Lilly Reports the P-III (EMBER-3) Trial Results of Imlunestrant to Treat ER+/HER2- Advanced Breast Cancer

Eli Lilly Reports the P-III (EMBER-3) Trial Results of Imlunestrant to Treat ER+/HER2- Advanced Breast Cancer

  • December 12, 2024
Eli Lilly to Highlight P-III (BRUIN CLL-321) Trial Data of Jaypirca (Pirtobrutinib) for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma at ASH 2024

Eli Lilly to Highlight P-III (BRUIN CLL-321) Trial Data of Jaypirca (Pirtobrutinib) for Chronic Lymphocytic Leukemia or Small Lymp...

  • December 10, 2024
Eli Lilly Reports Results from the P-IIIb (SURMOUNT-5) Trial of Zepbound (Tirzepatide) in Obese Adults

Eli Lilly Reports Results from the P-IIIb (SURMOUNT-5) Trial of Zepbound (Tirzepatide) in Obese Adults

  • December 4, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.